CRNX 240517 50.00P (CRNX240517P50000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CRNX240517P50000

Watchlist

2.00
-0.26-11.50%

15min DelayClose May 10 15:59 ET

2.00High0.60Low

Intraday

News

Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) Have Seen Solid Returns of 196% Over the Past Three Years
Yahoo FinanceMay 11 10:39 ET
Crinetics(CRNX.US) Officer Sells US$5.31 Million in Common Stock
$Crinetics(CRNX.US)$ Officer Struthers Richard Scott sold 107.45K shares of common stock on May 8, 2024 at an average price of $49.4 for a total value of $5.31 million.Source: Announcement What is sta
moomoo NewsMay 10 17:38 ET
Express News | Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersMay 10 17:38 ET
Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing
Richard Scott Struthers, Director, President & CEO, on May 08, 2024, sold 107,448 shares in Crinetics Pharmaceuticals (CRNX) for $5,307,931. Following the Form 4 filing with the SEC, Struthers has con
MT NewswiresMay 10 17:03 ET
Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow JonesMay 10 15:50 ET
Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
Yahoo FinanceMay 10 12:47 ET

Comments

Meltyy

8 hours ago

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics(UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Liquidia(LQDA.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$MorphoSys(MOR.US)$ Phase 3
$Immunocore(IMCR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$Capricor Therapeutics(CAPR.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3...

Meltyy

Mar 4 17:54

🎯 Ph 3 readouts in Q1 2024...

$Pfizer(PFE.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$ Phase 3
$Aquestive Therapeutics(AQST.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$Johnson & Johnson(JNJ.US)$ Phase 3

LuckyLuke

Feb 29 18:24

$Crinetics (CRNX.US)$ Overvalued 80%

Meltyy

Feb 26 14:34

4 Bio Readouts To Watch This Qtr

1. $Annovis Bio(ANVS.US)$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics(AXSM.US)$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics(GTHX.US)$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics(CRNX.US)$
• Ph 3 data (PATHFND...

Meltyy

Feb 22 12:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ $Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...